about
Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In VivoImmunologic characterization of a rhesus macaque H1N1 challenge model for candidate influenza virus vaccine assessment.Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1.Macrophage- and neutrophil-derived TNF-α instructs skin langerhans cells to prime antiviral immune responsesCross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIRC-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses.Brucella β 1,2 cyclic glucan is an activator of human and mouse dendritic cells.Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion.Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammationTranscriptional fingerprints of antigen-presenting cell subsets in the human vaginal mucosa and skin reflect tissue-specific immune microenvironments.A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40.Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cellsOpposing Roles of Dectin-1 Expressed on Human Plasmacytoid Dendritic Cells and Myeloid Dendritic Cells in Th2 Polarization.Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL primingSerum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation.Noncovalent assembly of anti-dendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo.Skin dendritic cells induce follicular helper T cells and protective humoral immune responses.Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell primingDendritic cells and vaccine design for sexually-transmitted diseases.Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T CellsCD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates.Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines.Influenza virus and poly(I:C) inhibit MHC class I-restricted presentation of cell-associated antigens derived from infected dead cells captured by human dendritic cells.Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.Harnessing human dendritic cell subsets for medicine.Building on dendritic cell subsets to improve cancer vaccines.Targeting human dendritic cell subsets for improved vaccines.Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity.Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses.Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo.Facile syntheses of functionalized toll-like receptor 7 agonistsFunctional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.Early SIV and HIV infection promotes the LILRB2/MHC-I inhibitory axis in cDCs.Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.F.140. Understanding Human Myeloid Dendritic Cell Subsets for the Rational Design of Novel VaccinesHIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates
P50
Q27300713-0ECE315C-950F-4BD3-98CD-DCE518D4A2F5Q30367637-1159D9B5-F859-46A4-8043-2D3BDDBADA19Q33723950-54224496-BD51-4201-8BA6-E0E233D31DD7Q34053805-6E4C9EEF-1637-4B11-97AB-A1C8B080944CQ34163004-04D4432B-F2DC-4D22-BE6E-1CD020EF4DF4Q34458766-3A710317-9C80-4BE9-8F81-65836F232208Q34481835-36BDBEDD-DDEA-4AFA-84A8-ED917F1CB04FQ34615273-5ACA77FE-43A4-4D0C-8FE4-32A50AD5622AQ34681491-9756542D-3FCA-4587-8C03-BC610E84B907Q34721358-CAF1DFEC-74AD-4701-AE6E-FA5C633D96CBQ35584127-4985BE90-BB19-4B25-94F8-76FBDCBCFD1CQ35679596-BC8B5B78-E2C1-427A-952D-D9BBAC86D00FQ35931761-95193BCA-328C-4985-B9B1-55F04AA05F72Q35989484-7CA8CCDB-D22A-4450-AEA3-1212E2740BC0Q36057590-C0BE247A-9451-40D2-8D94-3B0D1F512643Q36118295-9C1E4994-A072-4ED0-A4BF-7F8501D8D0C6Q36179478-63D9DEB6-D36C-438C-B645-24317A892286Q36264950-9868706E-0BBB-4136-A24E-5379C48E8894Q36414778-D6DDC00E-D7F8-4FB6-BD17-917F0208F617Q36681262-F0F15333-F1C7-4841-AB0D-FDF0424E84EEQ36754182-DB86BF6C-8316-47DD-9D8E-FFBDF5A37A4AQ36830663-1C971F0A-97C1-4B31-BBEE-9E84B23A2A39Q36948581-5719248D-7B18-46D4-86E0-3F22ABF1B733Q37149553-438D431D-0FC1-475E-AAAE-4641114E4D1DQ37385041-A5924CA7-C21A-4C1F-AB6E-A42C8C144CF6Q37700841-C5D1BC74-F692-4937-ACD5-F52A4A24B3DEQ37708502-6671F8A0-F239-41F8-AB59-8A3E148A87FFQ37833270-7CD52B3F-3A4E-4A92-B15D-E0BFCE7001B3Q38757011-ACD823EB-E508-443C-A5CF-6B67A5CBDEC3Q38835160-2866A933-CE8C-49A8-846B-DDD87A519705Q39664739-1AB6632B-FC27-40A2-952B-66E9984DD32EQ40867608-2E1FED31-7721-4E82-A331-A093EE0CD3EFQ42243654-EFADA3D0-0514-4043-9462-84BAA78AC042Q43120646-A7BFD699-11F2-42F6-82E7-90ED7079D281Q44843573-B057D639-B51C-47CE-8280-2F831EE74D79Q47215738-91011456-84B2-4994-AF71-472B2285C299Q49663116-E015E480-E759-43A2-8CD0-6F0512A5CB10Q57158492-ACC94533-7B8B-43BD-A226-604FEB095875Q60048646-4992A781-2428-4B46-88E8-81F3E3F39CA0
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-0168-3523
@en
name
Gerard Zurawski
@ast
Gerard Zurawski
@en
Gerard Zurawski
@es
Gerard Zurawski
@nl
type
label
Gerard Zurawski
@ast
Gerard Zurawski
@en
Gerard Zurawski
@es
Gerard Zurawski
@nl
prefLabel
Gerard Zurawski
@ast
Gerard Zurawski
@en
Gerard Zurawski
@es
Gerard Zurawski
@nl
P106
P21
P31
P496
0000-0002-0168-3523